ChEMBL ligand: CHEMBL4558803
BCL3 transcription coactivator/B-cell lymphoma 3 protein in Human [ChEMBL: CHEMBL4523197] [GtoPdb: 3232] [UniProtKB: P20749] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
BCL3 transcription coactivator/B-cell lymphoma 3 protein in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523197] [GtoPdb: 3232] [UniProtKB: P20749]
ChEMBL	Inhibition of FLAG-tagged Bcl-3 (unknown origin) expressed in HEK293 cells assessed as reduction in Bcl3 binding to its cognate protein partner NFKB1 (p50) incubated for 24 hrs by indirect sandwich ELISA	B	6.41	pIC50	385.5	nM	IC50	US-20160185740-A1. 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors (2016)
ChEMBL	Inhibition of Bcl-3 (unknown origin) in HEK293 cells co-expressing p52 assessed as reduction in NF-kappaB signalling incubated for 24 hrs by NF-kappaB promoter dependent luciferase reporter gene assay	B	6.68	pIC50	210.6	nM	IC50	US-20160185740-A1. 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors (2016)
ChEMBL	Inhibition of Bcl-3 (unknown origin) in HEK293 cells assessed as reduction in NF-kappaB signalling incubated for 24 hrs by NF-kappaB promoter dependent luciferase reporter gene assay	B	6.81	pIC50	156.6	nM	IC50	US-20160185740-A1. 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors (2016)
GtoPdb	Inhibition of Bcl3-mediated NF-kappaB signalling in human MDA-MB-231 cells, using a NF-kappaB promoter dependent luciferase reporter gene assay	-	7.34	pIC50	45.4	nM	IC50	WO2015014972A1. 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors (2015)
ChEMBL	Inhibition of Bcl-3 in human MDA-MB-231 cells assessed as reduction in NF-kappaB signalling incubated for 24 hrs by NF-kappaB promoter dependent luciferase reporter gene assay	B	7.34	pIC50	45.43	nM	IC50	US-20160185740-A1. 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors (2016)

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]